Perspective Therapeutics (CATX) to Release Earnings on Wednesday

Perspective Therapeutics (NYSE:CATX) is anticipated to post its quarterly earnings results after the market closes on Wednesday, March 26th. Analysts expect Perspective Therapeutics to post earnings of ($0.26) per share for the quarter.

Perspective Therapeutics Stock Up 1.2 %

Shares of NYSE CATX opened at $2.52 on Monday. Perspective Therapeutics has a fifty-two week low of $2.32 and a fifty-two week high of $19.05. The firm’s 50-day simple moving average is $3.03 and its 200 day simple moving average is $6.75.

Wall Street Analysts Forecast Growth

CATX has been the topic of a number of recent research reports. Bank of America cut Perspective Therapeutics from a “buy” rating to a “neutral” rating and cut their target price for the company from $24.00 to $5.00 in a research report on Monday, November 25th. Wedbush reaffirmed an “outperform” rating and set a $11.00 price objective on shares of Perspective Therapeutics in a report on Monday, March 17th. Lifesci Capital upgraded shares of Perspective Therapeutics to a “strong-buy” rating in a report on Thursday, March 6th. Cantor Fitzgerald upgraded shares of Perspective Therapeutics to a “strong-buy” rating in a report on Tuesday, March 4th. Finally, Brookline Capital Management upgraded shares of Perspective Therapeutics to a “strong-buy” rating in a research note on Monday, March 10th. One investment analyst has rated the stock with a hold rating, eight have given a buy rating and three have given a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $14.56.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.